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Introduction
Inherited or acquired dysregulation of the alternative complement pathway have been demonstrated to predispose to many cases of atypical hemolytic uremic syndrome (aHUS)(MIM 235400) 1 . This understanding of the pathogenesis of aHUS ultimately resulted in the successful introduction of the complement inhibitor eculizumab into the clinic 2 .
The term primary aHUS has been used when an underlying defect in the complement system is suspected (mutations in CFH, CFI, CFB, C3, CD46, or anti factor H antibodies) and secondary aHUS where there is another cause (e.g. infection associated, bone marrow transplant associated, drug-induced, cobalamin C disease etc.) 3 . Complicating such a classification is the finding that, in many cases a trigger (e.g. infection) is required for disease to manifest in those with a complement abnormality 1 . No biomarker exists that will confirm the diagnosis of a primary complement mediated aHUS in the acute setting and the diagnosis is therefore one of exclusion. Early initiation of eculizumab has been shown to lead to better outcomes 2 . Thus, treatment with eculizumab is often commenced in patients with suspected primary complement mediated aHUS, and discontinued if an alternative etiology is subsequently identified.
With the increasing use of eculizumab in clinical practice, it has become apparent that there are subgroups of non-complement mediated aHUS that do not respond to eculizumab (e.g.
DGKE 4 and INF2 5
). Additionally, a rare polymorphism in C5 has been demonstrated to impair eculizumab efficacy 6 .
Here we describe a child presenting with non-immune hemolysis, thrombocytopenia and acute kidney injury (AKI) who relapsed whilst on eculizumab and did not carry genetic risk factors for eculizumab non-response. Using whole exome sequencing we identified a pathogenic variant in G6PD (c.1160G>A, pR387H) that caused a phenotype indistinguishable from aHUS.
Case Presentation
A four-year-old boy presented to his local hospital with coryzal symptoms and macroscopic hematuria, having been treated with trimethoprim for a presumed UTI one week previously.
On presentation, he was profoundly anemic (hemoglobin 40g/L), with evidence of non- A presumptive diagnosis of primary complement-mediated aHUS was made and he was commenced on plasma exchange (PEX). Following initiation of PEX his renal function, hemoglobin, LDH, and platelets improved (figure 1). Six weeks following presentation he was commenced on eculizumab (600mg day 1 and 7, 300mg day 9, 300mg every fortnight thereafter) and PEX was discontinued.
Shortly after starting eculizumab, he contracted metapneumovirus and presented with acute deterioration of his hematological parameters (hemoglobin 77g/L, LDH 2248U/L and platelets of 121x10 9 /L) with stable creatinine; his third loading dose of eculizumab was brought forward and this episode settled.
He was maintained on eculizumab for 6 months, with adequate suppression of the alternative pathway (AH50 absent), although there was evidence of ongoing hemolysis (LDH above reference range and persistent anemia). Six months after commencing eculizumab, he presented with a lower respiratory tract infection. Despite evidence of effective complement blockade (AH50 absent), he was found to have acute hemolysis (hemoglobin 51g/L and LDH 4890U/L) and thrombocytopenia (platelet 123 x10 9 /L), without a change in serum creatinine. This settled spontaneously after treatment with intravenous antibiotics and a single blood transfusion.
Due to eculizumab resistance with chronic hemolysis, we undertook whole exome sequencing (as previously described 8 ) and identified a pathogenic variant in G6PD (c.1160G>A, pR387H). Functional erythrocyte G6PD activity levels confirmed severely depressed G6PD levels 0.4IU/10 12 erythrocytes (4.5 -13.5).
Following the decision to discontinue eculizumab, at 3 months the patient had one relapse, again associated with metapneumovirus infection, which required a blood transfusion, but without a change in his renal function or complement levels (C3 0.96mg/L, C4 0.32mg/L).
At last follow-up, 3 years after discontinuation of eculizumab he has not suffered any further acute relapses, although he has persistent chronic hemolysis (raised LDH and decreased hemoglobin) requiring folate supplementation.
Discussion
G6PD deficiency typically presents with hemolysis provoked by infection or drugs without AKI or thrombocytopenia. The presence of these features in this case lead to a delay in the eventual diagnosis.
Glucose 6 Phosphate dehydrogenase deficiency (MIM 134700) is an X-linked recessive condition, which occurs as a result of mutations in G6PD 9 . G6PD is ubiquitously expressed 10 and catalyzes the conversion of glucose-6-phosphate to 6-phosphoglucono-δ-lactone generating NADPH, in the first step of the pentose phosphate pathway 9 . This is the sole NADPH source within erythrocytes and is required to maintain the redox state intracellularly and prevent damage from free radical and reactive oxygen species produced during cellular metabolism 11 .
G6PD deficiency is classified (I to V) depending on enzyme activity 12 , with class I variants representing the most severe deficiency (activity <10%). Most individuals with G6PD deficiency remain asymptomatic but are susceptible to acute hemolytic crisis, due to oxidative damage, precipitated by infections, drugs or eating fava beans 9 . As with G6PD, primary complement mediated aHUS is frequently triggered by environmental stimuli. In addition to susceptibility to acute hemolytic crisis, individuals with class I variants suffer chronic non-spherocytic hemolytic anemia (CNSHA).
Within erythrocytes, oxidative damage leads to the formation of neoepitopes on band 3 protein on the cell membrane. This results in the binding of naturally occurring antibodies and ultimately C3b deposition and opsonization 13 . Clearance of these cells is thought to be, at least in part, complement dependent, mediated by CR1 14 . That hemolysis continued in this case, despite eculizumab indicates that the hemolysis and clearance of erythrocytes in G6PD
is independent of the terminal pathway of complement.
In vivo G6PD functions as a homodimer or tetramer 15 . The variant identified in this child, R387H, lies at this interface immediately adjacent to the β sheet strand "βL" (figure 2). This acts as a scaffold for both the dimer interface and NADP + binding. This variant has been described in patients with CNSHA and in keeping with this, functional analysis has demonstrated severely reduced G6PD (class I) activity 16 .
In this case, the patient presented with a clinical picture indistinguishable from aHUS, including AKI. AKI is a rare complication of acute hemolytic crisis in G6PD and is also seen in other hemolytic conditions such as paroxysmal nocturnal hemoglobinuria and sickle cell disease. Free hemoglobin released during hemolysis exceeds the binding capacity of haptoglobin, resulting in filtration of free hemoglobin and heme at the glomerulus. This leads to oxidative damage and apoptosis of the tubular cells with subsequent obstruction and acute tubular necrosis (ATN) 17 . Renal biopsies from patients with G6PD deficiency induced AKI, frequently demonstrate ATN 18 . Our patient has had one episode of AKI requiring dialysis;
renal biopsy was not performed due to thrombocytopenia. His renal function has returned to baseline, without any evidence of chronic damage in keeping with a presumed diagnosis of ATN.
Intriguingly, our patient developed thrombocytopenia during three of four acute hemolytic episodes, returning to normal when he was healthy. Mild thrombocytopenia has only rarely been reported during episodes of acute hemolytic crisis 19, 20 . Previous analysis has shown the activity of G6PD in platelets of patients with G6PD deficiency is severely reduced without an appreciable effect on their function although increased platelet microparticles have been reported, especially in severe deficiency 21 . R387H is one of the most severe variants in G6PD 16 ; and the thrombocytopenia in this case may be due to overwhelming oxidative stress.
In summary, we report a child presenting with non-immune hemolysis, thrombocytopenia
and AKI who did not respond to treatment with eculizumab. Using whole exome sequencing,
we identified a pathological variant in G6PD that likely caused the phenotype that is clinically indistinguishable from aHUS. This demonstrates the utility of next generation sequencing techniques in cases where there may be diagnostic uncertainty, allowing personalized management of these clinical syndromes.
G6PD is a rare but important differential diagnosis in patients presenting with an aHUS phenotype. The diagnosis of G6PD deficiency is most easily made by measuring reduced G6PD activity in erythrocytes. This test must be done whilst in remission, as there is a refractory period after acute hemolytic crisis where measured levels will be falsely elevated, as older erythrocytes with lower enzyme levels will be destroyed and only younger erythrocytes with higher residual G6PD levels are measured. We recommend testing for G6PD deficiency in aHUS patients, particularly in those who fail to respond to complement blockade, thus avoiding the risk and cost of long-term eculizumab treatment.
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